Research programme: diagnostic imaging - Bracco/Shire

Drug Profile

Research programme: diagnostic imaging - Bracco/Shire

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Bracco; Dyax
  • Developer Bracco; Shire
  • Class Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 22 Mar 2007 Preclinical development of diagnostic imaging agents is ongoing
  • 18 Jul 2001 Preclinical development for Undefined indication (diagnosis) in USA (unspecifed route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top